MX375283B - Compuesto hidroxitriazina y su uso medico. - Google Patents

Compuesto hidroxitriazina y su uso medico.

Info

Publication number
MX375283B
MX375283B MX2018002044A MX2018002044A MX375283B MX 375283 B MX375283 B MX 375283B MX 2018002044 A MX2018002044 A MX 2018002044A MX 2018002044 A MX2018002044 A MX 2018002044A MX 375283 B MX375283 B MX 375283B
Authority
MX
Mexico
Prior art keywords
compound
medical use
present
hydroxytriazine
hydroxytriazine compound
Prior art date
Application number
MX2018002044A
Other languages
English (en)
Spanish (es)
Other versions
MX2018002044A (es
Inventor
Ikuo Mitani
Masaki Yamashita
Yutaro Hirono
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2018002044A publication Critical patent/MX2018002044A/es
Publication of MX375283B publication Critical patent/MX375283B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2018002044A 2015-08-17 2016-08-16 Compuesto hidroxitriazina y su uso medico. MX375283B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015160284 2015-08-17
PCT/JP2016/073879 WO2017030115A1 (ja) 2015-08-17 2016-08-16 ヒドロキシトリアジン化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
MX2018002044A MX2018002044A (es) 2018-04-13
MX375283B true MX375283B (es) 2025-03-06

Family

ID=58052084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002044A MX375283B (es) 2015-08-17 2016-08-16 Compuesto hidroxitriazina y su uso medico.

Country Status (19)

Country Link
US (3) US20170057943A1 (enExample)
EP (2) EP4046991A1 (enExample)
JP (4) JP2017039714A (enExample)
KR (1) KR20180037270A (enExample)
CN (1) CN108137515B (enExample)
AR (1) AR105711A1 (enExample)
AU (1) AU2016309337B2 (enExample)
BR (1) BR112018001809A2 (enExample)
CA (1) CA2992410A1 (enExample)
CL (1) CL2018000430A1 (enExample)
CO (1) CO2018002516A2 (enExample)
IL (1) IL257559B (enExample)
MX (1) MX375283B (enExample)
PE (1) PE20180951A1 (enExample)
PH (1) PH12018500181A1 (enExample)
SG (1) SG11201800698VA (enExample)
TW (1) TWI704139B (enExample)
WO (1) WO2017030115A1 (enExample)
ZA (1) ZA201801134B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
JP2017039714A (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途
US10710967B2 (en) * 2015-10-29 2020-07-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
RU2648181C1 (ru) * 2017-05-25 2018-03-22 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения нейроретинопатии вследствие тяжелой преэклампсии
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
KR20250030486A (ko) * 2022-07-06 2025-03-05 아스카 세이야쿠 가부시키가이샤 피리미딘 유도체

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EA004656B1 (ru) 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
ES2398854T3 (es) 2007-04-03 2013-03-22 E. I. Du Pont De Nemours And Company Fungicidas de benceno sustituido
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Adeka 2,4,6−トリス(ヒドロキシフェニル)−1,3,5−トリアジン化合物の製造方法
US8716474B2 (en) 2008-06-04 2014-05-06 Adeka Corporation Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
WO2011037610A1 (en) * 2009-09-23 2011-03-31 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
CA2873984A1 (en) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) 2014-11-13 2016-05-18 东丽纤维研究所(中国)有限公司 一种拒水抗紫外纺织品及其生产方法和用途
JP2017039714A (ja) * 2015-08-17 2017-02-23 日本たばこ産業株式会社 ヒドロキシトリアジン化合物及びその医薬用途

Also Published As

Publication number Publication date
BR112018001809A2 (pt) 2018-09-18
CN108137515B (zh) 2021-07-06
JP7640658B2 (ja) 2025-03-05
US12492182B2 (en) 2025-12-09
TW201718524A (zh) 2017-06-01
SG11201800698VA (en) 2018-03-28
AU2016309337B2 (en) 2021-03-04
KR20180037270A (ko) 2018-04-11
RU2018109220A (ru) 2019-09-19
JP2020193235A (ja) 2020-12-03
CO2018002516A2 (es) 2018-05-31
JP2017039714A (ja) 2017-02-23
IL257559A (en) 2018-04-30
IL257559B (en) 2021-07-29
EP3339296A1 (en) 2018-06-27
JP2024019449A (ja) 2024-02-09
CL2018000430A1 (es) 2018-08-03
MX2018002044A (es) 2018-04-13
US20210024486A1 (en) 2021-01-28
CN108137515A (zh) 2018-06-08
EP4046991A1 (en) 2022-08-24
WO2017030115A1 (ja) 2017-02-23
RU2018109220A3 (enExample) 2019-11-15
US20240076278A1 (en) 2024-03-07
US20170057943A1 (en) 2017-03-02
PH12018500181A1 (en) 2018-07-30
AR105711A1 (es) 2017-11-01
ZA201801134B (en) 2019-07-31
CA2992410A1 (en) 2017-02-23
TWI704139B (zh) 2020-09-11
AU2016309337A1 (en) 2018-02-01
JP2022163169A (ja) 2022-10-25
EP3339296A4 (en) 2019-01-23
PE20180951A1 (es) 2018-06-11

Similar Documents

Publication Publication Date Title
PH12018500181A1 (en) Hydroxytriazine compound and medical use thereof
PH12016501651A1 (en) Triazine compound and use thereof for medical purposes
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
TN2017000158A1 (en) Carbazole derivatives
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
MY176631A (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
MX376283B (es) Compuestos de imidazopiridazina.
MX2015016771A (es) Compuestos de carbazol carboxamida utiles como inhibidores de cinasa.
MX2015014083A (es) Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1).
WO2016004404A3 (en) Gls1 inhibitors for treating disease
MX2017005060A (es) Compuestos atropisomeros triciclicos.
MX2017012188A (es) Inhibidores de beta-secretasa 1 (bace1).
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
TH1801000919A (th) สารประกอบไฮดรอกซิไทรแอซีนและการใช้ทางการแพทย์ของพวกมัน
EA037533B9 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
UA123899U (uk) Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази
TH1801004949A (th) สารประกอบคอนเดนเสดพิริมิดีนใหม่หรือเกลือของมัน
TH165163A (th) สารประกอบซับสทิทิวเทดเททระไฮโดรคาร์บาโซล และคาร์บาโซลคาร์บอกแชมีด ที่ใช้ประโยชน์เป็นสารยับยั้บการทำหน้าที่ของไคเนส

Legal Events

Date Code Title Description
FG Grant or registration